Algert Global’s scPharmaceuticals SCPH Stock Holding History

Algert Global’s Portfolio SCPH Stock Details SCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-13,860	Closed	-$73K	–	520
2020 Q4	$73K	Buy	+13,860	New	+$109K	0.02%	388

Other funds holding SCPH

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Algert Global's SCPH Position: Q1 2021 in Review

Algert Global sold out of scPharmaceuticals (SCPH) in Q1 2021, closing a stake of 13,860 shares — an estimated $73K sold.

Algert Global first reported a position in SCPH in Q4 2020 and held it in 1 quarter. The position peaked at $73K in Q4 2020. 46 funds tracked by Wall St. Rank hold SCPH as of Q1 2021.

Algert Global reported no remaining scPharmaceuticals position as of Q1 2021 after selling out during the quarter.
Algert Global sold 13,860 scPharmaceuticals shares in Q1 2021, an estimated $73K.
Algert Global first reported a position in scPharmaceuticals in Q4 2020 and held it in 1 quarter.
Algert Global's scPharmaceuticals position peaked at $73K in Q4 2020.
46 funds tracked by Wall St. Rank held scPharmaceuticals as of Q1 2021.

Based on Algert Global's 13F filing for Q1 2021, filed 14 May 2021.